Diverse alterations associated with resistance to KRAS(G12C) inhibition.

Autor: Zhao Y; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer, New York, NY, USA., Murciano-Goroff YR; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Xue JY; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer, New York, NY, USA.; Weill Cornell-Rockefeller-Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY, USA., Ang A; Amgen, Thousand Oaks, CA, USA., Lucas J; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer, New York, NY, USA., Mai TT; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer, New York, NY, USA., Da Cruz Paula AF; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Saiki AY; Amgen, Thousand Oaks, CA, USA., Mohn D; Amgen, Thousand Oaks, CA, USA., Achanta P; Amgen, Thousand Oaks, CA, USA., Sisk AE; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Arora KS; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Roy RS; Weill Cornell-Rockefeller-Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY, USA., Kim D; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer, New York, NY, USA., Li C; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer, New York, NY, USA., Lim LP; Resolution Bioscience, Kirkland, WA, USA., Li M; Resolution Bioscience, Kirkland, WA, USA., Bahr A; Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Loomis BR; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., de Stanchina E; Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Reis-Filho JS; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Weigelt B; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Berger M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Riely G; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Arbour KC; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lipford JR; Amgen, Thousand Oaks, CA, USA., Li BT; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lito P; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer, New York, NY, USA. litop@mskcc.org.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. litop@mskcc.org.; Weill Cornell-Rockefeller-Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY, USA. litop@mskcc.org.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. litop@mskcc.org.

Publikováno v: Nature [Nature] 2021 Nov; Vol. 599 (7886), pp. 679-683. Date of Electronic Publication: 2021 Nov 10.

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.

Autor: Canon J; Amgen Research, Amgen Inc, Thousand Oaks, CA, USA. jcanon@amgen.com., Rex K; Amgen Research, Amgen Inc, Thousand Oaks, CA, USA., Saiki AY; Amgen Research, Amgen Inc, Thousand Oaks, CA, USA., Mohr C; Amgen Research, Amgen Inc, Thousand Oaks, CA, USA., Cooke K; Amgen Research, Amgen Inc, Thousand Oaks, CA, USA., Bagal D; Amgen Research, Amgen Inc, South San Francisco, CA, USA., Gaida K; Amgen Research, Amgen Inc, Thousand Oaks, CA, USA., Holt T; Amgen Research, Amgen Inc, Thousand Oaks, CA, USA., Knutson CG; Amgen Research, Amgen Inc, Cambridge, MA, USA., Koppada N; Amgen Research, Amgen Inc, Cambridge, MA, USA., Lanman BA; Amgen Research, Amgen Inc, Thousand Oaks, CA, USA., Werner J; Amgen Research, Amgen Inc, Thousand Oaks, CA, USA., Rapaport AS; Amgen Research, Amgen Inc, South San Francisco, CA, USA., San Miguel T; Amgen Research, Amgen Inc, Thousand Oaks, CA, USA., Ortiz R; Amgen Research, Amgen Inc, Cambridge, MA, USA.; Pfizer, La Jolla, CA, USA., Osgood T; Amgen Research, Amgen Inc, Thousand Oaks, CA, USA., Sun JR; Amgen Research, Amgen Inc, Thousand Oaks, CA, USA., Zhu X; Amgen Research, Amgen Inc, Cambridge, MA, USA.; Takeda, Cambridge, MA, USA., McCarter JD; Amgen Research, Amgen Inc, Thousand Oaks, CA, USA., Volak LP; Amgen Research, Amgen Inc, Cambridge, MA, USA.; Celgene, San Diego, CA, USA., Houk BE; Amgen Clinical Development, Amgen Inc, Thousand Oaks, CA, USA., Fakih MG; City of Hope, Duarte, CA, USA., O'Neil BH; Indiana University School of Medicine, Indianapolis, IN, USA., Price TJ; The Queen Elizabeth Hospital, Woodville, South Australia, Australia.; University of Adelaide, Adelaide, South Australia, Australia., Falchook GS; Sarah Cannon Research Institute, Denver, CO, USA., Desai J; Peter MacCallum Cancer Center, Melbourne, Victoria, Australia., Kuo J; Scientia Clinical Research, Randwick, New South Wales, Australia., Govindan R; Washington University School of Medicine, St Louis, MO, USA., Hong DS; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ouyang W; Amgen Research, Amgen Inc, South San Francisco, CA, USA., Henary H; Amgen Clinical Development, Amgen Inc, Thousand Oaks, CA, USA., Arvedson T; Amgen Research, Amgen Inc, South San Francisco, CA, USA., Cee VJ; Amgen Research, Amgen Inc, Thousand Oaks, CA, USA., Lipford JR; Amgen Research, Amgen Inc, Thousand Oaks, CA, USA. jlipford@amgen.com.

Publikováno v: Nature [Nature] 2019 Nov; Vol. 575 (7781), pp. 217-223. Date of Electronic Publication: 2019 Oct 30.

The Role of MDM2 Amplification and Overexpression in Tumorigenesis.

Autor: Oliner JD; Jon Oliner Consulting, Garrett Park, Maryland 20896., Saiki AY; Oncology Research, Amgen, Thousand Oaks, California 91320., Caenepeel S; Oncology Research, Amgen, Thousand Oaks, California 91320.

Publikováno v: Cold Spring Harbor perspectives in medicine [Cold Spring Harb Perspect Med] 2016 Jun 01; Vol. 6 (6). Date of Electronic Publication: 2016 Jun 01.

The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.

Autor: Canon J; Department of Oncology Research, Amgen Inc., Thousand Oaks, California. jcanon@amgen.com., Osgood T; Department of Oncology Research, Amgen Inc., Thousand Oaks, California., Olson SH; Department of Medicinal Chemistry, Amgen Inc., San Francisco, California., Saiki AY; Department of Oncology Research, Amgen Inc., Thousand Oaks, California., Robertson R; Department of Oncology Research, Amgen Inc., Thousand Oaks, California., Yu D; Department of Oncology Research, Amgen Inc., Thousand Oaks, California., Eksterowicz J; Department of Molecular Structure, Amgen Inc., San Francisco, California., Ye Q; Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., San Francisco, California., Jin L; Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., San Francisco, California., Chen A; Department of Molecular Structure, Amgen Inc., San Francisco, California., Zhou J; Department of Molecular Structure, Amgen Inc., San Francisco, California., Cordover D; Department of Pathology, Amgen Inc., Thousand Oaks, California., Kaufman S; Department of Pathology, Amgen Inc., Thousand Oaks, California., Kendall R; Department of Oncology Research, Amgen Inc., Thousand Oaks, California., Oliner JD; Department of Oncology Research, Amgen Inc., Thousand Oaks, California., Coxon A; Department of Oncology Research, Amgen Inc., Thousand Oaks, California., Radinsky R; Department of Oncology Research, Amgen Inc., Thousand Oaks, California.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2015 Mar; Vol. 14 (3), pp. 649-58. Date of Electronic Publication: 2015 Jan 07.

Discovery of Potent and Simplified Piperidinone-Based Inhibitors of the MDM2-p53 Interaction.

Autor: Yu M; Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States., Wang Y; Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States., Zhu J; Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States., Bartberger MD; Departments of Therapeutic Discovery and Oncology Research, Amgen Inc. , One Amgen Center Drive, Thousand Oaks, California 91320, United States., Canon J; Departments of Therapeutic Discovery and Oncology Research, Amgen Inc. , One Amgen Center Drive, Thousand Oaks, California 91320, United States., Chen A; Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States., Chow D; Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States., Eksterowicz J; Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States., Fox B; Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States., Fu J; Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States., Gribble M; Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States., Huang X; Department of Therapeutic Discovery, Amgen Inc. , 360 Binney Street, Cambridge, Massachusetts 02142, United States., Li Z; Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States., Liu JJ; Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States., Lo MC; Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States., McMinn D; Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States., Oliner JD; Departments of Therapeutic Discovery and Oncology Research, Amgen Inc. , One Amgen Center Drive, Thousand Oaks, California 91320, United States., Osgood T; Departments of Therapeutic Discovery and Oncology Research, Amgen Inc. , One Amgen Center Drive, Thousand Oaks, California 91320, United States., Rew Y; Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States., Saiki AY; Departments of Therapeutic Discovery and Oncology Research, Amgen Inc. , One Amgen Center Drive, Thousand Oaks, California 91320, United States., Shaffer P; Department of Therapeutic Discovery, Amgen Inc. , 360 Binney Street, Cambridge, Massachusetts 02142, United States., Yan X; Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States., Ye Q; Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States., Yu D; Departments of Therapeutic Discovery and Oncology Research, Amgen Inc. , One Amgen Center Drive, Thousand Oaks, California 91320, United States., Zhao X; Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States., Zhou J; Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States., Olson SH; Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States., Medina JC; Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States., Sun D; Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.

Publikováno v: ACS medicinal chemistry letters [ACS Med Chem Lett] 2014 Jun 30; Vol. 5 (8), pp. 894-9. Date of Electronic Publication: 2014 Jun 30 (Print Publication: 2014).